Biomonitoring Equivalents for inorganic arsenic

Regulatory Toxicology and Pharmacology

Volumn 58, Issue 1, 2010, Pages 1-9

  Hays, Sean M ^a   Aylward, Lesa L ^a   Gagné, Michelle ^b   Nong, Andy ^c   Krishnan, Kannan ^b  

^a LLP   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HEALTH CANADA   (Canada)

Author keywords

Biomonitoring Equivalents; Inorganic arsenic; Pharmacokinetics; Risk assessment

Indexed keywords

ARSENIC DERIVATIVE; BIOLOGICAL MARKER; INORGANIC COMPOUND;

ARTICLE; BIOLOGICAL MONITORING; CANCER RISK; ENVIRONMENTAL EXPOSURE; HEALTH HAZARD; HUMAN; METABOLITE; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; STANDARDIZATION; TOXICOKINETICS; URINARY EXCRETION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARSENIC; BIOLOGICAL MARKERS; CHILD; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; ENVIRONMENTAL POLLUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; RISK ASSESSMENT; YOUNG ADULT;

EID: 77955917500     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.06.002     Document Type: Article

References (52)

1. Agusa T., Kunito T., Minh T.B., Kim Trang P.T., Iwata H., Viet P.H., Tanabe S. Relationship of urinary arsenic metabolites to intake estimates in residents of the Red River Delta, Vietnam. Environ. Pollut. 2009, 157:396-403.
2. Arbouine M.W., Wilson H.K. The effect of seafood consumption on the assessment of occupational exposure to arsenic by urinary arsenic speciation measurements. J. Trace Elem. Electrolytes Health Dis. 1992, 6:153-160.
3. Agency for Toxic Substances and Disease Registry (ATSDR), 2007. Toxicological Profile for Arsenic. US Department of Health and Human Services. Available from: <>http://www.atsdr.cdc.gov.
4. Aylward L.L., Hays S.M., Gagné M., Krishnan K. Derivation of Biomonitoring Equivalents for di(2-ethylhexyl)phthalate (CAS No. 117-81-7). Regul. Toxicol. Pharmacol. 2009, 55:249-258.
5. Buchet J.P., Lauwerys R., Roels H. Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int. Arch. Occup. Environ. Health 1981, 48:71-79.
6. Buchet J.P., Lauwerys R., Roels H. Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int. Arch. Occup. Environ. Health 1981, 48:111-118.
7. Buchet J.P., Pauwels J., Lauwerys R. Assessment of exposure to inorganic arsenic following ingestion of marine organisms by volunteers. Environ. Res. 1994, 66:44-51.
8. Calderon R.L., Hudgens E., Le X.C., Schreinemachers D., Thomas D.J. Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Environ. Health Perspect. 1999, 107:663-667.
9. Chu H.A., Crawford-Brown D.J. Inorganic arsenic in drinking water and bladder cancer: a meta-analysis for dose-response assessment. Int. J. Environ. Res. Public Health 2006, 3:316-322.
10. Cohen S.M., Arnold L.L., Eldan M., Lewis A.S., Beck B.D. Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit. Rev. Toxicol. 2006, 36:99-133.
11. El-Masri H.A., Kenyon E.M. Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites. J. Pharmacokinet. Pharmacodyn. 2008, 35:31-68.
12. Farmer J.G., Johnson L.R. Assessment of occupational exposure to inorganic arsenic based on urinary concentrations and speciation of arsenic. Br. J. Ind. Med. 1990, 47:342-348.
13. Gentry P.R., Covington T.R., Mann S., Shipp A.M., Yager J.W., Clewell H.J. Physiologically based pharmacokinetic modeling of arsenic in the mouse. J. Toxicol. Environ. Health A 2004, 67:43-71.
14. Hall M., Chen Y., Ahsan H., Slavkovich V., van Geen A., Parvez F., Graziano J. Blood arsenic as a biomarker of arsenic exposure: results from a prospective study. Toxicology 2006, 225:225-233.
15. Hays S.M., Aylward L.L. Using biomonitoring equivalents to interpret human biomonitoring data in a public health risk context. J. Appl. Toxicol. 2009, 29:275-288.
16. Hays S.M., Becker R., Leung H.W., Aylward L.L., Pyatt D.W. Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. Regul. Toxicol. Pharmacol. 2007, 47:96-109.
17. Hays S.M., Aylward L.L., LaKind J.S., Bartels M.J., Barton H.A., Boogaard P.J., Brunk P.J., Dizio S., Dourson M., Goldstein D.A., Lipscomb J., Kilpatrick M.E., Krewski D., Krishnan K., Nordberg M., Okino M., Tan Y.-M., Viau C., Yager J.W. Guidelines for the derivation of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul. Toxicol. Pharmacol. 2008, 51:S4-S15.
18. Health Canada, 2006. Guidelines for Canadian Drinking Water Quality: Guideline Technical Document - Arsenic. Water Quality and Health Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, Ontario.
19. Health Canada Food Division, 2007. Toxicological Reference Values, Estimated Daily Intakes, or Dietary Reference Values for Trace Elements. Last updated July 2007. Chemical Health Hazard Assessment Division, Bureau of Chemical Safety, Health Products and Food Branch, Health Canada.
20. Health Canada, 2008. Pest Management Regulatory Agency (PMRA). EPA/PMRA Joint Review of Chromated Copper Arsenate (CCA) Registration Re-evaluation. Available from: <>http://hc-sc.gc.ca/cps-spc/pubs/pest/_decisions/rev2008-08/index-eng.php.
21. Hughes M.F. Biomarkers of exposure: a case study with inorganic arsenic. Environ. Health Perspect. 2006, 114:1790-1796.
22. Kenyon E.M., Hughes M.F., Adair B.M., Highfill J.H., Crecelius E.A., Clewell H.J., Yager J.W. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water. Toxicol. Appl. Pharmacol. 2008, 232:448-455.
23. Kile M.L., Hoffman E., Hsueh Y.M., Afroz S., Quamruzzaman Q., Rahman M., Mahiuddin G., Ryan L., Christiani D.C. Variability in biomarkers of arsenic exposure and metabolism in adults over time. Environ. Health Perspect. 2009, 117:455-460.
24. LaKind J.S., Aylward L.L., Brunk C., DiZio S., Dourson M., Goldstein D.A., Kilpatrick M.E., Krewski D., Bartels M.J., Barton H.A., Boogaard P.J., Lipscomb J., Krishnan K., Nordberg M., Okino M., Tan Y.M., Viau C., Yager J.W., Hays S.M. Guidelines for the communication of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul. Toxicol. Pharmacol. 2008, 51:S16-S26.
25. Lauwerys R.R., Hoet P. Arsenic toxicokinetics. Industrial Chemical Exposure: Guidelines for Biological Monitoring 2001, CRC Press, LLC, Boca Raton, Florida. third ed.
26. Mage D.T., Allen R.H., Gondy G., Smith W., Barr D.B., Needham L.L. Estimating pesticide dose from urinary pesticide concentration data by creatinine correction in the Third National Health and Nutrition Examination Survey (NHANES-III). J. Expo. Anal. Environ. Epidemiol. 2004, 14:457-465.
27. Mann S., Droz P.O., Vahter M. A physiologically based pharmacokinetic model for arsenic exposure. I. Development in hamsters and rabbits. Toxicol. Appl. Pharmacol. 1996, 137:8-22.
28. Mann S., Droz P.O., Vahter M. A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. Toxicol. Appl. Pharmacol. 1996, 140:471-486.
29. Mizuta N., Mizuta M., Ito F., Ito T., Vchida H., Watanable Y., Akamura H., Murakami T., Hayashi F., Nakamura K., Yamagachi T., Mizua W., Oishi S., Matsumura H. An outbreak of acute arsenic poisoning caused by arsenic-contaminated soy-sauce (shoyu): a clinical report of 220 cases. Bull. Yamaguchi Med. Sch. 1956, 4:131-149.
30. Morales K.H., Ryan L., Kuo T.L., Wu M.M., Chen C.J. Risk of internal cancers from arsenic in drinking water. Environ. Health Perspect. 2000, 108:655-661.
31. Navas-Acien A., Guallar E. Measuring arsenic exposure, metabolism, and biological effects: the role of urine proteomics. Toxicol. Sci. 2008, 106:1-4.
32. Navas-Acien A., Umans J.G., Howard B.V., Goessler W., Francesconi K.A., Crainiceanu C.M., Silbergeld E.K., Guallar E. Urine arsenic concentrations and species excretion patterns in American Indian communities over a 10-year period: the Strong Heart Study. Environ. Health Perspect. 2009, 117:1428-1433.
33. National Research Council (NRC), 1999. Arsenic in Drinking Water. National Academy Press, Washington, DC.
34. Perucca J., Bouby N., Valeix P., Bankir L. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292:R700-R705.
35. Remer T., Neubert A., Maser-Gluth C. Anthropometry-based reference values for 24-h urinary creatinine excretion during growth and their use in endocrine and nutritional research. Am. J. Clin. Nutr. 2002, 75:561-569.
36. Remer T., Fonteyn N., Alexy U., Berkemeyer S. Longitudinal examination of 24-h urinary iodine excretion in schoolchildren as a sensitive, hydration status-independent research tool for studying iodine status. Am. J. Clin. Nutr. 2006, 83:639-646.
37. Rossman T.G. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat. Res. 2003, 533:37-65.
38. Schuhmacher-Wolz U., Dieter H.H., Klein D., Schneider K. Oral exposure to inorganic arsenic: evaluation of its carcinogenic and non-carcinogenic effects. Crit. Rev. Toxicol. 2009, 39:271-298.
39. Schwerdtle T., Walter I., Mackiw I., Hartwig A. Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured human cells and isolated DNA. Carcinogenesis 2003, 24:967-974.
40. Tam G.K., Charbonneau S.M., Bryce F., Pomroy C., Sandi E. Metabolism of inorganic arsenic (74As) in humans following oral ingestion. Toxicol. Appl. Pharmacol. 1979, 50:319-322.
41. Thomas D.J., Li J., Waters S.B., Xing W., Adair B.M., Drobna Z., Devesa V., Styblo M. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp. Biol. Med. (Maywood) 2007, 232:3-13.
42. Tseng W.P. Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ. Health Perspect. 1977, 19:109-119.
43. Tseng C.H. A review on environmental factors regulating arsenic methylation in humans. Toxicol. Appl. Pharmacol. 2009, 235:338-350.
44. Tseng W.P., Chu H.M., How S.W., Fong J.M., Lin C.S., Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J. Natl. Cancer Inst. 1968, 40:453-463.
45. US EPA, IRIS, 1993. Reference Dose Assessment. Available from: <> (accessed 14.05.09). http://www.epa.gov/NCEA/iris/subst/0278.htm.
46. US EPA. 2001. National primary drinking water regulation; arsenic and clarifications to compliance and new source contaminants monitoring; final rule. Fed. Regist. 66, 6975.
47. US EPA, 2008a. Hazard Identification and Toxicology Endpoint Selection for Inorganic Arsenic and Inorganic Chromium. Office of Prevention, Pesticides and Toxic Substances. J. Chen and T.F. McMahon, Office of Pesticide Programs Antimicrobials Division.
48. US EPA (United States Environmental Protection Agency), 2008b. Child-specific Exposure Factors Handbook. National Center for Environmental Assessment, Office of Research and Development. EPA/600/R-06/096F.
49. Vahter M. Methylation of inorganic arsenic in different mammalian species and population groups. Sci. Prog. 1999, 82(Pt 1):69-88.
50. Valentine J.L., Kang H.K., Spivey G. Arsenic levels in human blood, urine, and hair in response to exposure via drinking water. Environ. Res. 1979, 20:24-32.
51. Yu D. A pharmacokinetic modeling of inorganic arsenic: a short-term oral exposure model for humans. Chemosphere 1999, 39:2737-2747.
52. Yu D. A physiologically based pharmacokinetic model of inorganic arsenic. Regul. Toxicol. Pharmacol. 1999, 29:128-141.